Chang Yu Wang

Array ( [id] => 18831083 [patent_doc_number] => 20230399608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => PROCESS FOR ESTABLISHING A HUMAN TESTICULAR TISSUE CULTURE SYSTEM [patent_app_type] => utility [patent_app_number] => 18/346691 [patent_app_country] => US [patent_app_date] => 2023-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29002 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 323 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18346691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018902 [patent_doc_number] => 20240075073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => TREATING OPTIC NEURITIS WITH INDUCED PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PRECURSOR CELLS [patent_app_type] => utility [patent_app_number] => 18/217160 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10721 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18217160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879457 [patent_doc_number] => 20240002826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/340786 [patent_app_country] => US [patent_app_date] => 2023-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 146063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411984 [patent_doc_number] => 12077791 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof [patent_app_type] => utility [patent_app_number] => 18/339829 [patent_app_country] => US [patent_app_date] => 2023-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 145233 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18339829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692936 [patent_doc_number] => 20230323294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => DIFFERENTIATION OF CORTICAL NEURONS FROM HUMAN PLURIPOTENT STEM CELLS [patent_app_type] => utility [patent_app_number] => 18/325690 [patent_app_country] => US [patent_app_date] => 2023-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18325690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18989006 [patent_doc_number] => 20240060975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) [patent_app_type] => utility [patent_app_number] => 18/143917 [patent_app_country] => US [patent_app_date] => 2023-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18143917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065693 [patent_doc_number] => 20240100119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA [patent_app_type] => utility [patent_app_number] => 18/140919 [patent_app_country] => US [patent_app_date] => 2023-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18140919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830844 [patent_doc_number] => 20230399369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => WNT SIGNALING AGONIST MOLECULES [patent_app_type] => utility [patent_app_number] => 18/304018 [patent_app_country] => US [patent_app_date] => 2023-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18304018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612356 [patent_doc_number] => 20230279088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => FUSION PROTEIN COMPRISING A BLOOD-BRAIN BARRIER (BBB)-CROSSING SINGLE DOMAIN ANTIBODY FC5, AN IMMUNOGLOBULIN FC FRAGMENT AND A BETA-AMYLOID BINDING POLYPEPTIDE (ABP) [patent_app_type] => utility [patent_app_number] => 18/183812 [patent_app_country] => US [patent_app_date] => 2023-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18183812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879090 [patent_doc_number] => 20240002459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => Granulin Compositions and Uses Related Thereto [patent_app_type] => utility [patent_app_number] => 18/176859 [patent_app_country] => US [patent_app_date] => 2023-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483517 [patent_doc_number] => 20230210814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS [patent_app_type] => utility [patent_app_number] => 18/110960 [patent_app_country] => US [patent_app_date] => 2023-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18110960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709250 [patent_doc_number] => 20230331863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE AND HTT-LOWERING AGENT FOR TREATMENT OF HUNTINGTON'S DISEASE [patent_app_type] => utility [patent_app_number] => 18/168002 [patent_app_country] => US [patent_app_date] => 2023-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16003 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18168002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597229 [patent_doc_number] => 20230272023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => NGF VARIANTS, PRODUCTION, COMPOSITIONS, AND THERAPEUTIC USES [patent_app_type] => utility [patent_app_number] => 18/102214 [patent_app_country] => US [patent_app_date] => 2023-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18102214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391671 [patent_doc_number] => 20230159889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => USE OF N-BUTYLIDENEPHTHALIDE IN DOPAMINERGIC PROGENITOR CELL TRANSPLANTATION [patent_app_type] => utility [patent_app_number] => 18/160156 [patent_app_country] => US [patent_app_date] => 2023-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18160156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657698 [patent_doc_number] => 20230303644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => TREATMENT OF NERVOUS SYSTEM INJURY AND NEURODEGENERATIVE DISORDERS AND RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/159483 [patent_app_country] => US [patent_app_date] => 2023-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18159483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18510124 [patent_doc_number] => 20230226225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 18/150740 [patent_app_country] => US [patent_app_date] => 2023-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18150740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649531 [patent_doc_number] => 20230295347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => WNT RECEPTOR-SPECIFIC COMPOUND AND METHOD RELATING THERETO [patent_app_type] => utility [patent_app_number] => 18/148448 [patent_app_country] => US [patent_app_date] => 2022-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18148448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844524 [patent_doc_number] => 20230406928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER [patent_app_type] => utility [patent_app_number] => 18/147287 [patent_app_country] => US [patent_app_date] => 2022-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27646 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18147287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18550775 [patent_doc_number] => 20230248775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => GENETIC MODIFICATION OF MAMMALIAN CELLS TO CONFER RESISTANCE TO CSF1R ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/069631 [patent_app_country] => US [patent_app_date] => 2022-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19002027 [patent_doc_number] => 20240066098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/069546 [patent_app_country] => US [patent_app_date] => 2022-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069546 [rel_patent_id] =>[rel_patent_doc_number] =>)